1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: CH-BC-008, NCT01143974
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: BD-IC-IV08, NCT01665417
|
|
3.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: IFCT-GFPC-0701, NCT00651456
|
|
4.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TG4010.14/TIME, 8559, NCT01383148
|
|
5.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CIKLC-201004, NCT01481259
|
|
6.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: D7913L00077, NCT01579630
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00509, U10CA021115, CDR0000475774, E1505, ECOG-E1505, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805
|
|
8.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11514, H3E-MC-JMIG, NCT00686959
|
|
9.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9707, H3E-MC-JMHD, NCT00762034
|
|
10.
|
Phase: Phase III Type: Health services research, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ISRCTN02370070, CRUK-UCL-ET, EUDRACT-2007-007639-17, ET TRIAL, NCT00801736
|
|
11.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081007, NCT00932893
|
|
12.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13258, H3E-US-S130, NCT00948675
|
|
13.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SRSI-HSRL-02-2007, HSRL-02-2007, PROSE, 2007-006299-13, EU-20975, NCT00989690
|
|
14.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-30801, CALGB-30801, NCT01041781
|
|
15.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E5508, E5508, NCT01107626
|
|
16.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A8081014, NCT01154140
|
|
17.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 99-1896C, NCT01204307
|
|
18.
|
Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 70 and over Sponsor: Other Protocol IDs: EudraCT 2008-008372-13, NCT01257139
|
|
19.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DOCET_L_05478, NCT01282151
|
|
20.
|
Phase: Phase III Type: Supportive care Status: Active Age: 30 and over Sponsor: Pharmaceutical / Industry Protocol IDs: G300505, POWER2, NCT01355497
|
|
21.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-302, NCT01454934
|
|
22.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D791LC00001, NCT01544179
|
|
23.
|
Phase: Phase III Type: Treatment Status: Active Age: 70 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: AMC 2011-0857, NCT01593293
|
|
24.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: IFCT-GFPC-1101, NCT01631136
|
|
25.
|
Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: A8081029, NCT01639001
|